Posts tagged drug
Florida reporters win Al Nakkula Award for Police Reporting
Mar 4th
Two Florida reporters have won the 2014 Al Nakkula Award for Police Reporting from the University of Colorado Boulder’s Journalism and Mass Communication program and the Denver Press Club.
The $2,000 Nakkula prize goes to reporters Megan O’Matz and database editor John Maines of the South Florida Sun Sentinel for their series, “Cops, Cash, Cocaine.” The piece uncovered a police department’s secret scheme to lure drug dealers to a small town, entangle them in a sting and pocket money from the operation.
The award is named in honor of the late Al Nakkula, a 46-year veteran of the Rocky Mountain News whose tenacity made him a legendary police reporter, according to award organizers. The contest has existed since 1991 and this year drew more than two dozen entries from major publications around the country including the Los Angeles Times, the Seattle Times, the Boston Globe and Newsday.
Five veteran reporters, who worked at the Rocky Mountain News before its closure in 2009, judged the contest. Most of the reporters worked with Nakkula.
“The Sun Sentinel’s report stood out for the sheer doggedness of the reporting and the sheer audacity of the operation the newspaper exposed,” said Nakkula award judge Kevin Vaughan, an investigative reporter for Fox Sports.
Reporters O’Matz and Maines found that the Sunrise, Fla., police department enticed drug buyers to come to town, arrested them, confiscated their cash and cars and kept millions in proceeds. The officers who participated also received hundreds of thousands of dollars in overtime pay.
“ ‘Cops, Cash, Cocaine,’ was one of those stories that allowed Megan O’Matz and John Maines to deploy the skills they have become known for around here: piecing together bits of information, reviewing documents endlessly, talking to sources and checking things out in person. In other words: old-fashioned tenacity,” said Howard Saltz, Sun Sentinel editor.
“The result of their investigation not only revealed something that still boggles the mind when you read it, but served the community by forcing a highly unusual — and arguably dangerous — police operation to shut down,” he said.
O’Matz has received numerous state and national honors for previous work and was a 2006 finalist for the Pulitzer Prize in investigative reporting.
Series co-reporter Maines has been a database editor for the Sun Sentinel for 16 years. He and a Sun Sentinel colleague won the 2013 Pulitzer Prize for Public Service.
Second place in this year’s competition was awarded to reporters John Diedrich and Raquel Rutledge of the Milwaukee Journal Sentinel for their series, “Backfire.”
The judges also sent a special commendation to the staff of the Pittsburgh Post-Gazette for the depth and breadth of their work in 2013. The staff entered two major reporting projects in the contest.
For more information about the Al Nakkula award visit http://journalism.colorado.edu/al-nakkula-award/. For more information about CU-Boulder’s Journalism and Mass Communication program visit http://journalism.colorado.edu/.
-CU-
Space flight to test antibiotic’s effectiveness
Jan 3rd
education project on ants to space station
NASA Television will provide live coverage of the launch of Orbital Sciences Corp.’s commercial Cygnus spacecraft on Tuesday, Jan. 7 from NASA’s Wallops Flight Facility in Virginia, which will be carrying two University of Colorado Boulder payloads to the International Space Station.
The two CU-Boulder payloads — a biomedical antibiotic experiment and an educational K-12 experiment involving ant behavior in microgravity — are slated to be launched aboard Orbital Sciences Corp.’s Antares rocket at 11:55 a.m. MST. Both experiments were designed by BioServe Space Technologies, a NASA-funded center in CU-Boulder’s aerospace engineering sciences department.
The CU-Boulder biomedical experiment was designed to test the effectiveness of antibiotics in space. Past experiments by CU-Boulder and other institutions have shown bacterial susceptibility to antibiotics is significantly reduced during spaceflight, although the reason is not yet known, said CU-Boulder Associate Professor David Klaus, principal investigator on the project.
Klaus said the investigation will examine changes in the gene expression of the bacteria E. coli during exposure to different concentrations of antibiotics while in the microgravity environment of space. The hope is to locate particular genes that are key to resisting antibiotics, which could lead to improved testing on Earth as well as new drug targets or new approaches to understanding antibiotic resistance in certain diseases or infections, said Klaus.
“Previous studies carried out in microgravity have shown that bacteria are able to grow in what normally would be an inhibitory concentration of the antibiotic,” said Klaus. “This investigation is aimed at characterizing the genetic basis for this response in the weightless environment of space with the intent of applying any insight gained toward combating the increasing emergence of drug-resistant pathogens here on Earth.”
Co-investigators on the project include BioServe Director Louis Stodieck, a research professor in aerospace engineering, and Shawn Levy, a researcher at the HudsonAlpha Institute for Biotechnology in Huntsville, Ala. The research effort also involves CU-Boulder doctoral candidate Luis Zea.
Bacterial resistance to antibiotics kills 100,000 Americans every year and represents a roughly $20 billion expense to the U.S. government in excess health care costs, said Klaus. The experiments will be undertaken using spaceflight test tubes contained in the Commercial Generic Bioprocessing Apparatus, or CGBA, an automated, suitcase-sized incubator, all designed and built by BioServe.
The second experiment launching to ISS is known as Ants in Space, which examines foraging patterns based on the density of the common Pavement Ant, said BioServe Business Development Manager and Education Program Director Stefanie Countryman. “Past experiments by Professor Deborah Gordon, principal investigator on this project, have shown that some ant species have the ability to search areas collectively without individual communication. When ant densities are high, each ant thoroughly searches one small area in a circular, “random” walk, she said. When ant densities are low, each ant searches by walking in a relatively straight line, allowing it to cover more ground.
“Ants assess their own density at the rate at which they meet,” said Countryman, who said the eight individual ant habitats on ISS will be loaded with roughly 100 ants each. “The experiment examines whether in microgravity ants will use the rate at which they meet to assess density, and so use straighter paths in the larger habitat areas. The results will be compared to ground controls, which in this case will include ant habitats in hundreds of K-12 classrooms around the world.”
Countryman has previously directed BioServe K-12 education experiments involving the behavior of butterflies, ladybugs and spiders in space, reaching hundreds of thousands of students around the world in the past two decades. For the ant experiments, BioServe is partnering with the Baylor College of Medicine’s Center for Education Outreach, a longstanding BioServe partner that has developed the education curriculum guide for the experiment.
BioServe research partners on the ant project include Gordon of Stanford University and Associate Professor Michael Greene of the University of Colorado Denver. The experiment is sponsored by NASA’s National Lab Education Office as well as the Center for the Advancement of Science in Space, a nonprofit group headquartered in Cape Canaveral, Fla.
Teachers interested in participating in the ant experiments may contact Countryman at countrym@colorado.edu. More information on the project for teachers and students will be online beginning in mid-January at http://www.bioedonline.org.
The flight will be the first Cygnus resupply cargo mission launched to ISS by Orbital Sciences Corp. and follows the earlier, successful launch of a Cygnus demo flight to ISS that arrived at the orbiting station Oct. 22.
In the past 25 years, BioServe has designed, built and flown microgravity life science research experiments on more than 40 space missions. BioServe has a full suite of space flight hardware, both on ISS and on the ground, which supports its own research as well as research conducted by its customers and partners. Past BioServe partners include large and small pharmaceutical and biotechnology companies, universities and NASA-funded researchers.
For more information on BioServe visit http://www.colorado.edu/engineering/BioServe/index.html.
-CU-
CU Boulder researchers uncover new target for cancer research
Oct 25th
Researchers in the two scientists’ laboratories collaborated to find a patch of amino acids that, if blocked by a drug docked onto the chromosome end at this location, may prevent cancerous cells from reproducing. The amino acids at this site are called the “TEL patch” and once modified, the end of the chromosome is unable to recruit the telomerase enzyme, which is necessary for growth of many cancerous cells.
“This is an exciting scientific discovery that gives us a new way of looking at the problem of cancer,” Cech said. “What is amazing is that changing a single amino acid in the TEL patch stops the growth of telomeres. We are a long way from a drug solution for cancer, but this discovery gives us a different, and hopefully more effective, target.”
Cech is the director of the BioFrontiers Institute, a Howard Hughes Medical Investigator and winner of the 1989 Nobel Prize in chemistry.
Co-authors on the study include postdoctoral fellows Jayakrishnan Nandakumar and Ina Weidenfeld; University of Colorado undergraduate student Caitlin Bell; and Howard Hughes Medical Institute Senior Scientist Arthur Zaug.
Telomeres have been studied since the 1970s for their role in cancer. They are constructed of repetitive nucleotide sequences that sit at the ends of our chromosomes like the ribbon tails on a bow. This extra material protects the ends of the chromosomes from deteriorating, or fusing with neighboring chromosome ends. Telomeres are consumed during cell division and, over time, will become shorter and provide less cover for the chromosomes they are protecting. An enzyme called telomerase replenishes telomeres throughout their lifecycles.
Telomerase is the enzyme that keeps cells young. From stem cells to germ cells, telomerase helps cells continue to live and multiply. Too little telomerase produces diseases of bone marrow, lungs and skin. Too much telomerase results in cells that over proliferate and may become “immortal.” As these immortal cells continue to divide and replenish, they build cancerous tumors. Scientists estimate that telomerase activation is a contributor in up to 90 percent of human cancers.
To date, development of cancer therapies has focused on limiting the enzymatic action of telomerase to slow the growth of cancerous cells. With their latest discovery, Cech and Leinwand envision a cancer drug that would lock into the TEL patch at chromosome ends to keep telomerase from binding there. This approach of inhibiting the docking of telomerase may be the elegant solution to the complex problem of cancerous cells. Cech, a biochemist, and Leinwand, a biologist, joined forces to work on their latest solution.
“This work was really made possible by the fact that our labs are so close,” Leinwand said. “My lab was able to provide the cell biology and understanding of genetics, and Tom’s lab allowed us to explore the biochemistry. We have a unique situation at BioFrontiers where labs and people comingle to make discoveries just like this.”
Leinwand is the chief scientific officer of the BioFrontiers Institute and a professor of molecular, cellular and developmental biology.
Researchers at the University of Colorado have a significant history in developing marketable biotechnologies. Cech founded Ribozyme Pharmaceuticals Inc. Leinwand co-founded Myogen with CU professor Michael Bristow, Hiberna and recently launched MyoKardia (http://www.myokardia.com/about.php).
The BioFrontiers Institute is an interdisciplinary institute housed at the Jennie Smoly Caruthers Biotechnology Building at CU-Boulder. The institute is dedicated to training the next generation of interdisciplinary scientists through its IQ Biology Interdisciplinary Quantitative Biology Ph.D. program. For more information about BioFrontiers visithttp://biofrontiers.colorado.edu
–